Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Suramin, a novel antitumor compound.

R V La Rocca1, C A Stein, R Danesi

  • 1Medicine Branch, Clinical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.

The Journal of Steroid Biochemistry and Molecular Biology
|December 20, 1990
PubMed
Summary

Suramin, an antiparasitic drug, shows promise in treating various cancers by inhibiting critical growth factors and enzymes. Clinical trials are underway for adrenal cancer, refractory prostate cancer, and lymphomas.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Muscadine Grape Skin Extract in Biochemically Recurrent Prostate Cancer: A Randomized, Placebo-Controlled, Biomarker-Enriched Trial in Patients With the SOD2 Ala/Ala Variant.

The Prostate·2025
Same author

Overview of the early campaign diagnostics for the SPARC tokamak (invited).

The Review of scientific instruments·2024
Same author

Development of the neutral gas diagnostic system for neutral pressure measurements and gas analysis on the SPARC tokamak.

The Review of scientific instruments·2024
Same author

Development of a thermal diagnostic system for the SPARC tokamak.

The Review of scientific instruments·2024
Same author

Development of a bolometry diagnostic for SPARC.

The Review of scientific instruments·2024
Same author

Plasmoid Formation and Strong Radiative Cooling in a Driven Magnetic Reconnection Experiment.

Physical review letters·2024

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Suramin is a polyanionic compound initially developed as an antiparasitic agent.
  • It targets growth factor and enzyme systems essential for cell stability and multiplication.

Purpose of the Study:

  • To evaluate suramin's efficacy in treating cancers resistant to standard therapies.
  • To explore suramin's potential as a novel cancer therapeutic agent.

Main Methods:

  • Suramin's ability to bind and inactivate critical cellular growth and enzyme systems was investigated.
  • In vitro studies assessed suramin's cytostatic and cytocidal effects on human tumor cell lines.
  • Pilot clinical studies were conducted in patients with specific cancer types.

Main Results:

Related Experiment Videos

  • Suramin demonstrated significant cytostatic and cytocidal effects against various human tumor cell lines in vitro.
  • The compound exhibits adrenocorticolytic properties in vivo.
  • Pilot studies included patients with adrenocortical carcinoma, refractory prostate cancer, and nodular lymphomas.

    • Conclusions:

    • Suramin's unique mechanism of action supports its investigation for refractory cancers.
    • Further clinical trials are warranted to establish suramin's therapeutic role in oncology.